Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC424 versus best available therapy in hydroxyurea-resistant or -intolerant polycythemia vera
NL-OMON41591Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruxolitinib in polycythemia vera (PV), sponsored by Novartis. Started Jun 2011; status: active, not recruiting.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NL-OMON41591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41591.